Liv Hege Aksnes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Liv Hege Aksnes has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Kirsten Sundby Hall
Department of Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
2 shared publications A.A. Dahl
Faculty Division, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway
1 shared publicationAlv A. Dahl
University of Oslo
1 shared publicationAnna Elisabeth Stenwig
Department of Pathology, The Norwegian Radium Hospital, Montebello, 0310, Oslo, Norway
1 shared publicationBodil Bjerkehagen
Department of Pathology, The Norwegian Radium Hospital, Montebello, 0310, Oslo, Norway
1 shared publicationC. Allert
Department of Physiotherapy Karolinska University Hospital, SE-17176 Stockholm, Sweden
1 shared publication
Latest Publications
- 2 April 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (1) , 84-89
Health status at long‐term follow‐up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: A Scandinavian sarcoma group study
Background: The purpose of this study was to evaluate late effects and symptom complaints in long‐term survivors (>5 years) of Extremity Bone Sarcoma (EBS survivors). The results were compared with findings in age‐ and gender‐matched individuals from the general population (NORMs).Patients and Methods: Among 155 EBS survivors approached, 133 (86%) were included, and 110 of them (83%) attended an outpatient examination. Health status was evaluated by a mailed questionnaire concerning demographic and current health issues, and physical examinations at the outpatient clinic. Age‐ and gender‐adjusted normative controls were drawn from participants of the Health Study of Nord‐Trøndelag County (HUNT 2).Results: Median age at follow‐up was 29 (15–57) years. Median follow‐up was 12 (6–22) years. Of EBS survivors 42% had ≥1 somatic disease, 33% had ototoxicity and 13% had reduced renal function. EBS survivors were more likely to have heart disease (odds ratio [OR], 7.9; 95% confidence interval [95% CI], 2.5–25.3; P = 0.001), hypertension (OR, 3.4; 95% CI, 1.1–10.1; P = 0.03) and thyroid disease (OR, 3.0; 95% CI, 1.1–8.3; P = 0.04) compared to NORMs. EBS survivors reported more diarrhoea (29% vs. 19%, P = 0.02), palpitations (23% vs. 13%, P = 0.01) and shortness of breath (11% vs. 5%, P = 0.01) than NORMs.Conclusions: EBS survivors have poorer health status compared to age‐ and gender‐matched controls. Long‐term follow‐up of these patients is therefore mandatory. Pediatr Blood Cancer 2009;53:84–89.
- 2 April 2009
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 53 (1) , 84-89
Health status at long‐term follow‐up in patients treated for extremity localized Ewing Sarcoma or osteosarcoma: A Scandinavian sarcoma group study
Background: The purpose of this study was to evaluate late effects and symptom complaints in long‐term survivors (>5 years) of Extremity Bone Sarcoma (EBS survivors). The results were compared with findings in age‐ and gender‐matched individuals from the general population (NORMs).Patients and Methods: Among 155 EBS survivors approached, 133 (86%) were included, and 110 of them (83%) attended an outpatient examination. Health status was evaluated by a mailed questionnaire concerning demographic and current health issues, and physical examinations at the outpatient clinic. Age‐ and gender‐adjusted normative controls were drawn from participants of the Health Study of Nord‐Trøndelag County (HUNT 2).Results: Median age at follow‐up was 29 (15–57) years. Median follow‐up was 12 (6–22) years. Of EBS survivors 42% had ≥1 somatic disease, 33% had ototoxicity and 13% had reduced renal function. EBS survivors were more likely to have heart disease (odds ratio [OR], 7.9; 95% confidence interval [95% CI], 2.5–25.3; P = 0.001), hypertension (OR, 3.4; 95% CI, 1.1–10.1; P = 0.03) and thyroid disease (OR, 3.0; 95% CI, 1.1–8.3; P = 0.04) compared to NORMs. EBS survivors reported more diarrhoea (29% vs. 19%, P = 0.02), palpitations (23% vs. 13%, P = 0.01) and shortness of breath (11% vs. 5%, P = 0.01) than NORMs.Conclusions: EBS survivors have poorer health status compared to age‐ and gender‐matched controls. Long‐term follow‐up of these patients is therefore mandatory. Pediatr Blood Cancer 2009;53:84–89.
- 1 June 2008
- Published by British Editorial Society of Bone & Joint Surgery in The Journal of Bone and Joint Surgery. British volume
- Vol. 90-B (6) , 786-794
Limb-sparing surgery preserves more function than amputation
We evaluated the long-term functional outcome in 118 patients treated for osteosarcoma or Ewing’s sarcoma in the extremities a minimum of five years after treatment. We also examined if impaired function influenced their quality of life and ability to work.The function was evaluated according to the Musculoskeletal Tumor Society (MSTS) score and the Toronto Extremity Salvage Score (TESS). Quality of life was assessed by using the Short Form-36 (SF-36).The mean age at follow-up was 31 years (15 to 57) and the mean follow-up was for 13 years (6 to 22). A total of 67 patients (57%) initially had limb-sparing surgery, but four had a secondary amputation. The median MSTS score was 70% (17% to 100%) and the median TESS was 89% (43% to 100%). The amputees had a significantly lower MSTS score than those with limb-sparing surgery (p < 0.001), but there was no difference for the TESS. Tumour localisation above knee level resulted in significantly lower MSTS scores and TESS (p = 0.003 and p = 0.02, respectively).There were no significant differences in quality of life between amputees and those with limb-sparing surgery except in physical functioning. Of the patients 11% (13) did not work or study. In multivariate analysis, amputation, tumour location above the knee and having muscular pain were associated with low physical function.We conclude that most of the bone tumour survivors managed well after adjustment to their physical limitations. A total of 105 are able to work and have an overall good quality of life.
- 1 June 2008
- Published by British Editorial Society of Bone & Joint Surgery in The Journal of Bone and Joint Surgery. British volume
- Vol. 90-B (6) , 786-794
Limb-sparing surgery preserves more function than amputation
We evaluated the long-term functional outcome in 118 patients treated for osteosarcoma or Ewing’s sarcoma in the extremities a minimum of five years after treatment. We also examined if impaired function influenced their quality of life and ability to work.The function was evaluated according to the Musculoskeletal Tumor Society (MSTS) score and the Toronto Extremity Salvage Score (TESS). Quality of life was assessed by using the Short Form-36 (SF-36).The mean age at follow-up was 31 years (15 to 57) and the mean follow-up was for 13 years (6 to 22). A total of 67 patients (57%) initially had limb-sparing surgery, but four had a secondary amputation. The median MSTS score was 70% (17% to 100%) and the median TESS was 89% (43% to 100%). The amputees had a significantly lower MSTS score than those with limb-sparing surgery (p < 0.001), but there was no difference for the TESS. Tumour localisation above knee level resulted in significantly lower MSTS scores and TESS (p = 0.003 and p = 0.02, respectively).There were no significant differences in quality of life between amputees and those with limb-sparing surgery except in physical functioning. Of the patients 11% (13) did not work or study. In multivariate analysis, amputation, tumour location above the knee and having muscular pain were associated with low physical function.We conclude that most of the bone tumour survivors managed well after adjustment to their physical limitations. A total of 105 are able to work and have an overall good quality of life.
- Open Access
- 9 March 2007
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 15 (9) , 1087-1096
Young survivors of malignant bone tumours in the extremities: a comparative study of quality of life, fatigue and mental distress
Purpose The purpose of the study was to compare the quality of life (QoL), fatigue and mental distress in survivors of malignant extremity bone tumours (EBT survivors) with age and gender-matched survivors of Hodgkin’s disease (HD survivors) and testicular cancer (TC survivors) as well as normative samples from the general population. Patients and methods Five years or more after end of treatment, 75 EBT survivors were mailed a questionnaire containing Short Form-36 (SF-36), the Hospital Anxiety and Depression Scale, the Fatigue Questionnaire and questions about demography. Fifty-eight EBT survivors responded. TC survivors, HD survivors and normative samples (NORMs) had earlier on filled in the same questionnaire. For EBT survivors, gender and age-matched controls were randomly selected among TC survivors, HD survivors and NORMs. Results No significant differences in the fatigue or mental distress scores were observed between the survivor groups. The EBT survivors had significantly higher fatigue scores and lower depression scores than NORMs and significantly lower scores on all physical dimensions of QoL than TC survivors, HD survivors and NORMs. In multivariate analysis, a low level of education and lack of employment were significantly associated with caseness of mental distress. Older age at survey, female gender, being an EBT survivor and lack of employment were associated with caseness on the SF-36 Physical Component Summary Scale. Conclusion At long-term follow-up, EBT survivors did not show impaired mental health or fatigue at the group level, although their post-treatment status was characterised by reduced QoL dimensions on physical function compared to TC survivors, HD survivors and NORMs.
- 9 March 2007
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 15 (9) , 1087-1096
Open AccessYoung survivors of malignant bone tumours in the extremities: a comparative study of quality of life, fatigue and mental distress
Purpose The purpose of the study was to compare the quality of life (QoL), fatigue and mental distress in survivors of malignant extremity bone tumours (EBT survivors) with age and gender-matched survivors of Hodgkin’s disease (HD survivors) and testicular cancer (TC survivors) as well as normative samples from the general population. Patients and methods Five years or more after end of treatment, 75 EBT survivors were mailed a questionnaire containing Short Form-36 (SF-36), the Hospital Anxiety and Depression Scale, the Fatigue Questionnaire and questions about demography. Fifty-eight EBT survivors responded. TC survivors, HD survivors and normative samples (NORMs) had earlier on filled in the same questionnaire. For EBT survivors, gender and age-matched controls were randomly selected among TC survivors, HD survivors and NORMs. Results No significant differences in the fatigue or mental distress scores were observed between the survivor groups. The EBT survivors had significantly higher fatigue scores and lower depression scores than NORMs and significantly lower scores on all physical dimensions of QoL than TC survivors, HD survivors and NORMs. In multivariate analysis, a low level of education and lack of employment were significantly associated with caseness of mental distress. Older age at survey, female gender, being an EBT survivor and lack of employment were associated with caseness on the SF-36 Physical Component Summary Scale. Conclusion At long-term follow-up, EBT survivors did not show impaired mental health or fatigue at the group level, although their post-treatment status was characterised by reduced QoL dimensions on physical function compared to TC survivors, HD survivors and NORMs.
- Open Access
- 1 January 2006
- Published by Taylor & Francis in Acta Oncologica
- Vol. 45 (1) , 38-46
Management of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience
All cases of high-grade osteosarcoma (OS) (n = 196) and Ewing's sarcoma of bone (ES) (n = 56) treated at the Norwegian Radium Hospital in the period 1980–1999 were analyzed retrospectively. They were allocated to consecutive ten-year periods by their time of diagnosis. Patient and tumour characteristics have been relatively stable. Eighty percent of all patients received surgical treatment and the amputation rate decreased from 64% to 23%. The percentage of patients receiving chemotherapy has remained around 80%. The use of radiotherapy in primary treatment decreased gradually from 33% to 18%. Sarcoma specific survival (SSS) at five years for all patients increased significantly from 39% to 53%. Similar trends for improvement were seen for both OS and ES. In multivariate analysis, independent prognostic factors for improved SSS were non-metastatic disease at diagnosis, age under 40, extremity tumours, small tumours and treatment from 1995 onwards. No major new treatment options have emerged over these 20 years. The improved outcome appears partly to be due to refinements in the use of existing modalities and improved quality and integration of multidisciplinary approaches. Improved formalized organisation of the sarcoma group and annual audited reports of its patient and research activity may also have contributed to improved focus and performance.
- 1 January 2006
- Published by Taylor & Francis in Acta Oncologica
- Vol. 45 (1) , 38-46
Open AccessManagement of high-grade bone sarcomas over two decades: The Norwegian Radium Hospital experience
All cases of high-grade osteosarcoma (OS) (n = 196) and Ewing's sarcoma of bone (ES) (n = 56) treated at the Norwegian Radium Hospital in the period 1980–1999 were analyzed retrospectively. They were allocated to consecutive ten-year periods by their time of diagnosis. Patient and tumour characteristics have been relatively stable. Eighty percent of all patients received surgical treatment and the amputation rate decreased from 64% to 23%. The percentage of patients receiving chemotherapy has remained around 80%. The use of radiotherapy in primary treatment decreased gradually from 33% to 18%. Sarcoma specific survival (SSS) at five years for all patients increased significantly from 39% to 53%. Similar trends for improvement were seen for both OS and ES. In multivariate analysis, independent prognostic factors for improved SSS were non-metastatic disease at diagnosis, age under 40, extremity tumours, small tumours and treatment from 1995 onwards. No major new treatment options have emerged over these 20 years. The improved outcome appears partly to be due to refinements in the use of existing modalities and improved quality and integration of multidisciplinary approaches. Improved formalized organisation of the sarcoma group and annual audited reports of its patient and research activity may also have contributed to improved focus and performance.